Amvuttra (vutrisiran) Letter of Medical Necessity
Amvuttra (vutrisiran) is a quarterly TTR silencer approved for both ATTR cardiomyopathy and hereditary ATTR polyneuropathy. It is usually billed on the medical benefit, and ATTR-CM requests are often reviewed against tafamidis step therapy. A strong Letter of Medical Necessity proves the diagnosis and explains why vutrisiran is the right choice.
FDA-Approved Indications
- ● cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults
- ● polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR-PN) in adults
Why Amvuttra Prior Authorization Gets Denied
The most common denial reasons across major payers:
- 1. ATTR-CM diagnosis not confirmed (no technetium scintigraphy with light-chain exclusion, or no biopsy)
- 2. NYHA class and baseline cardiac measures not documented
- 3. Step therapy through tafamidis required by plan policy
- 4. Concurrent tafamidis or another TTR silencer not justified
- 5. Billed under the wrong benefit or missing HCPCS code for a clinician-administered drug
What to Include in a Amvuttra Letter of Medical Necessity
For ATTR-CM, attach the technetium pyrophosphate or DPD scintigraphy (Perugini grade 2–3) with serum and urine immunofixation and free light chains excluding AL amyloidosis, or a tissue biopsy, plus TTR genotyping, NYHA class, NT-proBNP, and echocardiographic findings. For hATTR-PN, include the pathogenic variant and neuropathy staging. Address any tafamidis history and state whether combination therapy is intended.
Key clinical evidence to cite:
- ✓ HELIOS-B Phase 3 trial — reduced all-cause mortality and recurrent cardiovascular events in ATTR-CM
- ✓ HELIOS-A Phase 3 trial — improved mNIS+7 and quality of life in hATTR polyneuropathy
- ✓ Quarterly subcutaneous dosing administered by a healthcare professional
Relevant guidelines:
- 📖 ACC 2023 Expert Consensus on Cardiac Amyloidosis
- 📖 AHA/ACC/HFSA 2022 Heart Failure Guideline
- 📖 European ATTR Amyloidosis Network Recommendations
Amvuttra Prior Authorization Criteria
Standard criteria across major US payers for Amvuttra. Specific criteria vary by plan — RxCheckUp tailors each LMN to your patient's exact payer policy.
Typical step therapy requirements:
- → Step therapy through tafamidis required by plan policy
Required documentation:
- ✓ ICD-10 diagnosis code with specificity
- ✓ Prior therapy history with dates, doses, and discontinuation reasons
- ✓ Specialist evaluation (where applicable)
- ✓ Baseline disease activity or biomarker results
- ✓ Clinical rationale citing FDA labeling or guidelines
Approval details:
Initial approval: typically 6 months. Renewal: 12 months with documented clinical response.
Payers Covering Amvuttra
RxCheckUp tailors each LMN to the specific payer's medical policy and step therapy requirements:
Amvuttra Prior Authorization FAQ
Why was my Amvuttra prior authorization denied?
The most common denial reasons for Amvuttra are: ATTR-CM diagnosis not confirmed (no technetium scintigraphy with light-chain exclusion, or no biopsy); NYHA class and baseline cardiac measures not documented; Step therapy through tafamidis required by plan policy; Concurrent tafamidis or another TTR silencer not justified; Billed under the wrong benefit or missing HCPCS code for a clinician-administered drug.
What should a Amvuttra Letter of Medical Necessity include?
For ATTR-CM, attach the technetium pyrophosphate or DPD scintigraphy (Perugini grade 2–3) with serum and urine immunofixation and free light chains excluding AL amyloidosis, or a tissue biopsy, plus TTR genotyping, NYHA class, NT-proBNP, and echocardiographic findings. For hATTR-PN, include the pathogenic variant and neuropathy staging. Address any tafamidis history and state whether combination therapy is intended.
Which payers cover Amvuttra?
Amvuttra is covered by major US payers including Medicare Part B, UnitedHealthcare, Aetna, Humana, Cigna, Anthem BCBS, though formulary tier and prior authorization criteria vary.